Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoni Ribas

Showing results (1-10 of 467) with videos related to

Pageof 47
Sort By:
The Oncologist|November 15, 2008
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206)Antoni Ribas
The New England Journal of Medicine|June 5, 2012
Tumor immunotherapy directed at PD-1Antoni Ribas
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Novel insights/translational implication from the emerging biology of melanomaAntoni Ribas
Seminars in Oncology|November 16, 2010
Clinical development of the anti-CTLA-4 antibody tremelimumabAntoni Ribas
Pigment Cell & Melanoma Research|May 26, 2012
Immunoediting the cancer genome--a new approach for personalized cancer therapy?Antoni Ribas
Seminars in Oncology|December 13, 2005
Clinical trials with tumor antigen genetically modified dendritic cellsAntoni Ribas
Cancer Discovery|April 3, 2021
T Cells as the Future of Cancer TherapyAntoni Ribas
Cancer Discovery|August 15, 2015
Adaptive Immune Resistance: How Cancer Protects from Immune AttackAntoni Ribas
Lancet (London, England)|June 15, 2020
Triple therapy for BRAF<sup>V600</sup>-mutated melanomaAntoni Ribas
Current Gene Therapy|February 7, 2006
Genetically modified dendritic cells for cancer immunotherapyAntoni Ribas
Pageof 47

Showing results (1-10 of 467) with videos related to

Sort By:
Pageof 47
The Oncologist|November 15, 2008
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206)Antoni Ribas
The New England Journal of Medicine|June 5, 2012
Tumor immunotherapy directed at PD-1Antoni Ribas
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Novel insights/translational implication from the emerging biology of melanomaAntoni Ribas
Seminars in Oncology|November 16, 2010
Clinical development of the anti-CTLA-4 antibody tremelimumabAntoni Ribas
Pigment Cell & Melanoma Research|May 26, 2012
Immunoediting the cancer genome--a new approach for personalized cancer therapy?Antoni Ribas
Seminars in Oncology|December 13, 2005
Clinical trials with tumor antigen genetically modified dendritic cellsAntoni Ribas
Cancer Discovery|April 3, 2021
T Cells as the Future of Cancer TherapyAntoni Ribas
Cancer Discovery|August 15, 2015
Adaptive Immune Resistance: How Cancer Protects from Immune AttackAntoni Ribas
Lancet (London, England)|June 15, 2020
Triple therapy for BRAF<sup>V600</sup>-mutated melanomaAntoni Ribas
Current Gene Therapy|February 7, 2006
Genetically modified dendritic cells for cancer immunotherapyAntoni Ribas
Pageof 47